Skip to content

Investigating the Effect of Using Myopia Prediction Algorithm on Myopia Children

Investigating the Effect of Using Myopia Prediction Algorithm on Myopia Children's Eye Refraction in China: a Multi-center Randomized Control Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04044755
Enrollment
2138
Registered
2019-08-05
Start date
2019-08-03
Completion date
2020-11-30
Last updated
2019-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Errors

Brief summary

In this study, the investigators aim to perform a prospective, randomized controlled study to compare the myopia development between myopia children using myopia prediction algorithm and myopia children without using myopia prediction algorithm

Detailed description

We propose to enroll myopia children aged 8-10 in China. Children will be given examinations of visual acuity, eye refraction and biometrics, and be assigned to two groups: participants in group A use myopia prediction algorithm to predict myopia development, while in Group B, the participants do not use myopia prediction algorithm to predict myopia development. The visual acuity, eye refraction and biometrics will be investigated over the one-year follow-up period, aiming at comparison of actual myopia development between the two groups

Interventions

Candidate predictors mainly includes age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Masking description

The outcomes assessors involved in data management and analysis will be blinded to the group assignment. The study participants, the investigators responsible for randomization will not be masked.

Eligibility

Sex/Gender
ALL
Age
8 Years to 10 Years
Healthy volunteers
Yes

Inclusion criteria

* Children aged 8-10 * Has the record of eye refraction examined in the past year, SER\<-0.5D * Current BCVA≥0.8, SER\<-0.5D, Astigmatism less than 1.50 D, anisometropia less than 1.50 D * Written informed consents provided

Exclusion criteria

* Definitive diagnosis of other diseases except for refractive error * Previous eye surgery * Previous usage of orthokeratology lenses and atropine * Unwilling to participate in this trial

Design outcomes

Primary

MeasureTime frameDescription
Incidence of SER development of at least -0.5 dioptres (D)up to 1 yearSER: spherical equivalent refraction, sphere + ½ 360 cylinder; SER development of at least -0.5 dioptres: SER2 - SER1≤-0.5D; SER1: SER at baseline; SER2: SER up to 1 year

Secondary

MeasureTime frameDescription
Changes in SER \ and ALUp to 1 yearChanges in SER \\ and AL will be calculated; AL: axial length
Changes in proportion of children using atropineUp to 1 yearChanges in proportion of children using atropine will be calculated
Changes in proportion of children using orthokeratology lensesUp to 1 yearChanges in proportion of children using orthokeratology lenses will be calculated
Incidence of SER development of at least -1.0 dioptres (D)Up to 2 yearSER: spherical equivalent refraction, sphere + ½ 360 cylinder; SER development of at least -1.0 dioptres: SER2 - SER1≤-0.5D; SER1: SER at baseline; SER2: SER up to 2 year
Changes in child's average outdoor activity time per dayUp to 1 yearChanges in child's average outdoor activity time per day will be calculated
Changes in child's average screen time per dayUp to 1 yearChanges in child's average screen time per day will be calculated
Changes in proportion of children using spectaclesUp to 1 yearChanges in proportion of children using spectacles will be calculated

Countries

China

Contacts

Primary ContactYahan Yang
yah.yang39@hotmail.com+8615521013933
Backup ContactHaotian Lin
haot.lin@hotmail.com+8613802793086

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026